Lupin and Novartis resolve patent dispute over hypertension drug

Indian pharmaceutical company Lupin and Swiss pharmaceutical group Novartis have reached an out-of court settlement over Novartis's hypertension drug sold under the brand name Lotrel, reported The Economic Times.

According to the news source, the settlement allows Lupin to launch a generic version of the drug ahead of its patent expiry in 2017 and get a one-time revenue upside.

Lupin intends to launch its generic version of Lotrel, a combination of amlodipine besylate and benazepril hydrochloride, within the next few years.

Lupin develops and markets a range of generic formulations and active pharmaceutical ingredients globally.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: patent, pharmaceuticals, revenue